ERAXIS DIN 02330695
Health Canada record
| Active ingredient(s) | ANIDULAFUNGIN 100 MG |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J02AX06 ANIDULAFUNGIN |
| Original market date | 25-Jan-2010 |
| Current status date | 25-Jan-2010 |
| Source | Health Canada DPD |
Establishment licence of the holder
Pfizer Canada ULC — licence 100255, currently licensed, last inspection rating C (2023-08-07).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ANIDULAFUNGIN
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02302160 | ERAXIS | PFIZER CANADA ULC | Powder For Solution | ANIDULAFUNGIN 100 MG | Cancelled Post Market |
| 02441683 | GD-ANIDULAFUNGIN | GENMED A DIVISION OF PFIZER CANADA ULC | Powder For Solution | ANIDULAFUNGIN 100 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 10452 | 2009-07-28 | Supplement to a New Drug Submission (SNDS) | New presentation without solvent |
International API supply for ANIDULAFUNGIN
3 active FDA Drug Master Files.
Request a quote for ERAXIS